ALRN News and Press, Aileron Therapeutics Inc. From 04/30/21

Chemotherapy is built into the treatment regime of nearly every cancer. However, chemotherapy's well-known toxicity can lead to patient discontinuation and poor quality-of-life. Aileron is developing a treatment to address the toxicity of chemotherapy. For further details se...

2020 marked a year of successful evolution to a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients -- Advancing selective chemoprotection via p53 biomarker strategy; 50% of all cancer patients acros...

Innovation, R&D and an aging population are long-term secular trends that will provide a tailwind to the biotechnology sector. The Insurgent AI Deep Innovation Model uses Deep Learning and secular tailwinds to generate alpha. Evaluating investment strategies is challenging, es...

The following slide deck was published by Aileron Therapeutics, Inc. in conjunction with this event. For further details see: Aileron Therapeutics (ALRN) Investor Presentation - Slideshow

WATERTOWN, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the 2021 H.C. Wainwright Global Life Sciences Conference, which is taking pla...

-- Placebo-controlled trial anticipated to enroll 60 patients with advanced p53-mutated NSCLC undergoing treatment with first-line carboplatin plus pemetrexed -- -- Trial anticipated to begin in second quarter 2021 with initial data anticipated at the end of 2021 and final...

Today we provide an in-depth look at a small cap biotech stock called Aileron Therapeutics that trades around $1.50 a share. Since coming public just over three years ago the stock has sold off deeply into Busted IPO territory. The company does have an intriguing early stage pipel...

Aileron Therapeutics has a long history of not doing much. Its data is early stage, but the scientific theory is interesting. The company needs cash. For further details see: Aileron Therapeutics: Low Cash Balance, Early Stage, But Scientific Premise Is Interesting

Analysts Rate These Penny Stocks A Buy Right Now The thought of making money with penny stocks is always the favored goal, right? It’s simple, just buy then sell for a profit. But as easy as that sounds, there’s a lot more that goes into the actual strategy of day trad...

Top Penny Stocks For Your Biotech Watch List This Week With 2021 well on its way, the time to find penny stocks to buy is now. But before making any large investment, it’s important to understand what is going on in the stock market today. Given that the pandemic is still ris...